UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549



FORM 10-Q



|[x] | QUARTERLY REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
        FOR THE QUARTERLY PERIOD ENDED  February
        28, 2015
|--- | ---------------------------------------------------------------------------------------------------------------------------------------------------------



OR



|[ ] | TRANSITION REPORT UNDER SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
        FOR THE TRANSITION PERIOD FROM _______ TO ________.
|--- | ----------------------------------------------------------------------------------------------------------------------------------------------



COMMISSION FILE NUMBER: 0-52518



EVENT CARDIO GROUP INC.

(Exact Name of Registrant as Specified in its Charter)



|Nevada                                                                                            |  | 20 - 8051714       
|------------------------------------------------------------------------------------------------- |  | -------------------
|(State or other jurisdiction of                                                                   |  | (I.R.S. Employer   
|incorporation or organization)                                                                    |  | Identification No.)
|                                                                                                  |  |                    
|2798
                                         Thamesgate Dr.
        Mississauga, Ontario, Canada |  | L4T 4E8            
|(Address of principal executive offices)                                                          |  | (Zip code)         



Issuer's telephone number:
89-407-4377



(Address of principal executive offices)



Indicate by check mark whether the registrant (1) has filed all reports required to
be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period
that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes [x] No [ ]



Indicate by check mark whether the registrant has submitted electronically and posted
on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation
S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required
to submit and post such files).

Yes [x] No [ ]



Indicate by check mark whether the registrant is a large accelerated filer, an accelerated
filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,”
“accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.



|Large accelerated filer [ ]                                             |  | Accelerated filer [ ]        
|----------------------------------------------------------------------- |  | -----------------------------
|Non-accelerated filer [ ] (Do not check if a smaller reporting company) |  | Smaller reporting company [x]



Indicate by check mark whether the registrant is a shell company (as defined in Rule
12b-2 of the Exchange Act). Yes [ ] No [x]



As of April 1, 2015, 93,847,702 shares of Common Stock, $0.001 par value, were outstanding
excluding 1,412,619 shares owned by our subsidiary.









EVENT CARDIO
GROUP INC.

CONTENTS
TO FORM 10-Q



|              |                                                                                                           | Page
|------------- | --------------------------------------------------------------------------------------------------------- | ----
|PART I --     | FINANCIAL INFORMATION                                                                                     |     
|Item 1.       | Financial Statements (Unaudited)                                                                          | 1   
|              | Consolidated Balance Sheets at February 28, 2015 (Unaudited) and August 31, 2014                          | 1   
|              | Consolidated Statements of Operations for the Six Months ended February 28, 2015 (Unaudited)              | 2   
|              | Statements of Changes in Stockholders’ Deficit for the Six Months ended February
    28, 2015 (Unaudited) | 3   
|              | Unaudited Consolidated Statements of Cash Flows for the Six Months ended February 28, 2015 (Unaudited)    | 4   
|              | Notes to Unaudited Consolidated Financial Statements                                                      | 5   
|Item 2.       | Management’s Discussion and Analysis of Financial Condition and Results of Operations                     | 10  
|Item 3.       | Quantitative and Qualitative Disclosures about Market Risk                                                | 14  
|Item 4.       | Controls and Procedures                                                                                   | 14  
|              |                                                                                                           |     
|PART II -     | OTHER INFORMATION                                                                                         | 15  
|Item 1.       | Legal Proceedings                                                                                         | 15  
|Item 2.       | Unregistered Sales of Equity Securities and Use of Proceeds from Sales of Registered Securities           | 15  
|Item 3.       | Defaults Upon Senior Securities                                                                           | 15  
|Item 4.       | Mine Safety Disclosures                                                                                   | 15  
|Item 5.       | Other Information                                                                                         | 15  
|Item 6.       | Exhibits                                                                                                  | 15  
|Signatures    |                                                                                                           | 16  
|Exhibit/Index |                                                                                                           |     













PART I - FINANCIAL INFORMATION



ITEM 1.  FINANCIAL STATEMENTS



EVENT CARDIO GROUP INC.

CONSOLIDATED BALANCE SHEETS

AS OF FEBRUARY 28, 2015 AND AUGUST 31, 2014

(Unaudited)



|                                                                                                                                                                        |  | February 28, 2015 |            | August 31, 2014
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------- |  | ----------------- | ---------- | ---------------
|                                                                                                                                                                        |  |                   |            |                
|ASSETS:                                                                                                                                                                 |  |                   |            |                
|Current Assets                                                                                                                                                          |  |                   |            |                
|Cash                                                                                                                                                                    |  | $                 | 52,384     |                
|Prepaid expenses                                                                                                                                                        |  |                   | 354,750    |                
|Total Current Assets                                                                                                                                                    |  |                   | 407,134    |                
|Property and Equipment, net                                                                                                                                             |  |                   | 1,926      |                
|Financing Costs, net                                                                                                                                                    |  |                   | 20,884     |                
|Intangible Asset                                                                                                                                                        |  |                   | 501,064    |                
|TOTAL ASSETS                                                                                                                                                            |  | $                 | 931,008    |                
|                                                                                                                                                                        |  |                   |            |                
|LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT):                                                                                                                         |  |                   |            |                
|Current Liabilities                                                                                                                                                     |  |                   |            |                
|Accounts payable                                                                                                                                                        |  | $                 | 232,500    |                
|Payables pursuant to license agreement                                                                                                                                  |  |                   | 12,500     |                
|Due to related parties                                                                                                                                                  |  |                   | 82,047     |                
|Total Current Liabilities                                                                                                                                               |  |                   | 327,047    |                
|Long-Term Debt - Related Parties                                                                                                                                        |  |                   | 529,354    |                
|TOTAL LIABILITIES                                                                                                                                                       |  |                   | 856,401    |                
|Stockholders' Equity (deficit)                                                                                                                                          |  |                   |            |                
|Preferred stock, $0.001 par value; 10,000,000 shares authorized, 10,000,000 shares issued and outstanding                                                               |  |                   | —          |                
|Common stock,190,000,000 shares authorized at $0.001 par value, 79,500,000 common shares issued and outstanding at August 31, 2014  and 95,260,321 at February 28, 2015 |  |                   | 95,260     |                
|Additional paid in capital                                                                                                                                              |  |                   | 951,187    |                
|Accumulated other comprehensive income                                                                                                                                  |  |                   | 81,520     |                
|Accumulated deficit                                                                                                                                                     |  |                   | (1,053,360 | )              
|Total Event Cardio Group Inc. stockholders' 			equity (deficiency)                                                                                                      |  |                   | 74,607     |                
|Non-controlling interest                                                                                                                                                |  |                   | —          |                
|TOTAL STOCKHOLDERS' EQUITY (DEFICIT)                                                                                                                                    |  |                   | 74,607     |                
|TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)                                                                                                                    |  | $                 | 931,008    |                

Table of Contents1





EVENT CARDIO GROUP INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

FOR THE SIX MONTHS ENDED FEBRUARY
28, 2015 and 2014

(Unaudited)



|                                            |  | Three Months Ended February 28 |            | Six Months Ended February 28
|------------------------------------------- |  | ------------------------------ | ---------- | ----------------------------
|                                            |  | 2015                           |            | 2014                        
|                                            |  |                                |            |                             
|Revenue                                     |  | $                              | —          |                             
|Operating Expenses                          |  |                                |            |                             
|General and administrative                  |  |                                | 214,227    |                             
|Research and development                    |  |                                | 55,599     |                             
|Total Operating Expenses                    |  |                                | 269,826    |                             
|Loss from Operations                        |  |                                | (269,826   | )                           
|Other Expense                               |  |                                |            |                             
|Interest expense - related parties          |  |                                | 20,479     |                             
|Net Loss                                    |  |                                | (290,305   | )                           
|Other Comprehensive Income                  |  |                                |            |                             
|Foreign currency translation adjustment     |  |                                | 92,677     |                             
|Total Comprehensive Loss                    |  | $                              | (197,628   | )                           
|Loss per Share - Basic and	Diluted          |  | $                              | (0.00      | )                           
|Weighted Average Shares - Basic and Diluted |  |                                | 90,301,774 |                             

Table of Contents2





EVENT CARDIO GROUP INC.

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)

FOR THE SIX MONTHS ENDED FEBRUARY 28, 2015

(Unaudited)



|                                                                   |  | Common Stock                                   |            |        |  |                            |        |                                        |  |                     |         |                         
|------------------------------------------------------------------ |  | ---------------------------------------------- | ---------- | ------ |  | -------------------------- | ------ | -------------------------------------- |  | ------------------- | ------- | ------------------------
|                                                                   |  | Number of Common Shares Issued and Outstanding |            | Amount |  | Additional Paid in Capital |        | Accumulated Other Comprehensive Income |  | Accumulated Deficit |         | Non-Controlling Interest
|                                                                   |  |                                                |            |        |  |                            |        |                                        |  |                     |         |                         
|Balance, September 1, 2014                                         |  |                                                | 79,500,000 |        |  | $                          | 79,500 |                                        |  | $                   | —       |                         
|Effect of reverse merger                                           |  |                                                | 6,882,773  |        |  |                            | 6,883  |                                        |  |                     | —       |                         
|Issued for cash                                                    |  |                                                | 1,750,000  |        |  |                            | 1,750  |                                        |  |                     | 195,250 |                         
|Issued as settlement of 		payables pursuant to 		license agreement |  |                                                | 2,827,548  |        |  |                            | 2,827  |                                        |  |                     | 373,237 |                         
|Issued for services                                                |  |                                                | 4,300,000  |        |  |                            | 4,300  |                                        |  |                     | 382,700 |                         
|Net comprehensive income (loss)                                    |  |                                                | —          |        |  |                            | —      |                                        |  |                     | —       |                         
|Balance, February 28, 2015                                         |  |                                                | 95,260,321 |        |  | $                          | 95,260 |                                        |  | $                   | 951,187 |                         



Table of Contents3





EVENT CARDIO GROUP INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE SIX MONTHS ENDED FEBRUARY 28, 2015 and 2014

(Unaudited)



|                                                                            |  | Six Months Ended February 28,
|--------------------------------------------------------------------------- |  | -----------------------------
|                                                                            |  | 2015                         
|                                                                            |  |                              
|Cash Flows from Operating Activities                                        |  |                              
|Net loss                                                                    |  | $                            
|Adjustments to reconcile net loss to net cash used in operating activities: |  |                              
|Depreciation                                                                |  |                              
|Amortization of prepaid expenses                                            |  |                              
|Amortization of financing costs                                             |  |                              
|Changes in assets and liabilities:                                          |  |                              
|Accounts payable                                                            |  |                              
|Net cash used in operating activities                                       |  |                              
|                                                                            |  |                              
|Cash Flows from Investing Activities                                        |  |                              
|Purchase of intangible asset                                                |  |                              
|Net cash used in investing activities                                       |  |                              
|                                                                            |  |                              
|Cash Flows from Financing Activities                                        |  |                              
|Advances on due from related parties                                        |  |                              
|Proceeds from long-term debt - related parties                              |  |                              
|Proceeds from issuance of common shares                                     |  |                              
|Net cash provided by financing activities                                   |  |                              
|Effect of exchange rate on cash                                             |  |                              
|Decrease in Cash                                                            |  |                              
|Cash, beginning of period                                                   |  |                              
|Cash, end of period                                                         |  | $                            



Table of Contents4





EVENT CARDIO GROUP INC.

NOTES TO FINANCIAL STATEMENTS

February 28, 2015 and August 31, 2014



1. OVERVIEW



Description of Business



Sunrise Holdings Limited was incorporated on
October 26, 2005 under the laws of Nevada. It changed its name to Event Cardio Group Inc. (the "Company") on November
7, 2014. The Company is developing a cardiac monitoring device based on a wireless and leadless advance cardiac monitor. Upon
completion of the development the device will collect medical data and transmit it to physicians for diagnostic evaluation. The
Company also has a license agreement to distribute a patented product in the use of breast disease detection.



The Company has elected to adopt early application
of Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting
Requirements and does not present or disclose inception-to-date information and other remaining disclosure requirements of Topic
915.



Going Concern



As shown in the accompanying financial
statements, the Company has not generated any revenue since inception, has incurred losses, and has an accumulated deficit of
$1,053,360 as of February 28, 2015. These factors among others raise substantial doubt about the ability of the Company to continue
as a going concern. The Company’s continuation as a going concern is dependent on its ability to generate sufficient cash
flows from operations to meet its obligations, which it has not been able to accomplish to date, and/or obtain additional financing
from its stockholders and/or other third parties.



These financial statements have been prepared on a going concern
basis, which implies the Company will continue to meet its obligations and continue its operations for the next fiscal year. The
continuation of the Company as a going concern is dependent upon financial support from its stockholders, the ability of the Company
to obtain necessary equity financing to continue operations, successfully locating and negotiating with other business entities
for potential acquisitions and/or acquiring new clients to generate revenues. There is no assurance that the Company will ever
be profitable. These financial statements do not include any adjustments to reflect the possible future effects on the recoverability
and classification of assets or the amounts and classifications of liabilities that may result should the Company be unable to
continue as a going concern.



Basis of Presentation



The unaudited consolidated financial statements have been prepared
in accordance with accounting principles generally accepted in the United States of America for interim financial statements and
with the instructions to Form 10-Q and Article 10 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”).
Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United
States of America for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited
consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present
the financial position of the Company as of February 28, 2015 and the results of operations and cash flows for the periods
presented. The results of operations for the six months ended February 28, 2015 are not necessarily indicative of the operating
results for the full fiscal year or any future period. These consolidated financial statements should be read in conjunction with
the consolidated financial statements and related notes thereto included in the form 8-K/A filed with the SEC on November 26,
2014.

These financial statements contain
the accounts of the Company and the accounts of the Company's subsidiaries 2340960 Ontario Inc. and EFIL Sub of ECG Inc. as at
February 28, 2015 and August 31, 2014 Any inter-company accounts and transactions are eliminated.

Table of Contents5







EVENT CARDIO GROUP INC.

NOTES TO FINANCIAL STATEMENTS

February 28, 2015 and August 31, 2014



1. OVERVIEW (continued)



The financial statements have been
prepared in conformity with accounting principles generally accepted in the United States of America and are presented in United
States Dollars.



2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES



Use of Estimates



In preparing these financial statements
in conformity with GAAP, management is required to make estimates and assumptions that may affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported
amount of revenues and expenses during the reporting years. Actual results could differ from those estimates.



Fair Value Measurements



ASC 820, “Fair Value Measurements”, requires
an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC
820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure
fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input
that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure
fair value: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets or liabilities;
Level 2, inputs other than level one that are either directly or indirectly observable such as quoted prices for identical or
similar assets or liabilities on markets that are not active; and Level 3, defined as unobservable inputs in which little or no
market data exists, therefore requiring an entity to develop its own assumptions. The Company had no assets or liabilities required
to be recorded at fair value on a recurring basis as of February 28, 2015 or August 31, 2014.



Cash and Cash Equivalents



The Company considers all highly-liquid investments
with maturities of three months or less when purchased to be cash equivalents. The Company had no cash equivalents as of
February 28, 2015 or August 31, 2014.



Concentration of Credit Risk



Financial instruments that potentially subject
the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company places its cash with
high quality banking institutions.



Income Taxes



Under ASC 740, "Income Taxes", deferred
tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial
statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities
are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are
expected to be recovered or settled. Valuation allowances are established when it is more likely than not that some or all of
the deferred tax assets will not be realized.

Table of Contents6





EVENT CARDIO GROUP INC.

NOTES TO FINANCIAL STATEMENTS

February 28, 2015 and August 31, 2014



2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)



In assessing the realization of deferred tax
assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized.
The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in
which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities,
projected future taxable income and tax planning strategies in making this assessment. Based on the assessment, the Company has
established a full valuation allowance against all of the deferred tax assets for every period because it is more likely than
not that all of the deferred tax assets will not be realized.



The Company files income tax returns in Canada and the United
States with varying statutes of limitations. The Company's policy is to recognize interest expense and penalties related to income
tax matters as a component of our provision for income taxes. There were no accrued interest and penalties associated with uncertain
tax positions as of February 28, 2015.



Foreign Currency Translation



The Company's reporting and functional currency
is the U.S. dollar. The Company's Canadian operation's functional currency is the Canadian dollar. The Company's U.S. subsidiary's
functional currency is the U.S. dollar.



Transactions originating in Canadian dollars
are translated to the functional currency of the US dollar as follows: using year end rates of exchange for financial assets and
liabilities, average rates of exchange for the period of transactions for revenues and expenses and historical rates for property
and equipment and equity.



The financial statements of the Company's Canadian
operations are translated from the functional currency of the Canadian dollar into the reporting currency of the United States
dollar in accordance with ASC 830, Foreign Currency Matters, using year end rates of exchange for assets and liabilities, average
rates of exchange for the period for revenues and expenses and historical rates for equity.



Translation adjustments resulting from the
process of translating the functional currency of Canadian dollar Canadian operation's financial statements into the reporting
currency of U.S. dollar financial statements are included in determining comprehensive income. As of February 28, 2015 and August
31, 2014, the cumulative translation adjustment of $81,519 and $4,999 respectively was classified as an item in accumulated other
comprehensive income in the stockholders' deficit section of the balance sheet. For the period ended February 28, 2015 and February
28, 2014, the foreign currency translation adjustment to accumulated other comprehensive income was $76,521 and $nil respectively.



Comprehensive Loss



Comprehensive loss is defined to include all
changes in equity except those resulting from investments by owners and distributions to owners. Among other disclosures, Accounting
Standards Codification (ASC) 200, Comprehensive Income, requires that all items that are required to be recognized under current
accounting standards as components of comprehensive income be reported in a financial statement that is displayed with the same
prominence as other financial statements. For the year presented, the Company's comprehensive loss includes net loss and foreign
currency translation adjustments and is presented in the statement of comprehensive loss.



Property and Equipment



Property and equipment consists of computer
equipment, and is stated at cost. Property and equipment is depreciated using the straight-line method over the estimated service
life of three years. Maintenance and repairs are expensed as incurred and improvements are capitalized. Gains or losses on the
disposition of property equipment are recorded upon disposal.

Table of Contents7





EVENT CARDIO GROUP INC.

NOTES TO FINANCIAL STATEMENTS

February 28, 2015 and August 31, 2014



2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)



Research and Development Expenses



All research and development costs are expensed
as incurred.



Intangible Asset



License agreement is carried at cost, net of
any impairment charges.



Impairment of Long-Lived Assets



Long-lived assets are reviewed for impairment
whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability
of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future
cash flows expected to be generated by the asset.



If the carrying amount of an asset exceeds
its undiscounted estimated future cash flows, an impairment review is performed. An impairment charge is recognized in the amount
by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented
in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated.
The assets and liabilities of a disposed group classified as held for sale would be presented separately in the appropriate asset
and liability sections of the balance sheet. For the periods ended February 28, 2015 and August 31, 2014 there was an impairment
charge of $nil and $nil, respectively with respect to license agreement.



3. PROPERTY & EQUIPMENT



Property and equipment consist of the following
as of February 28, 2015 and August 31, 2014:



|                         |  | February 28, 2015 |       | August 31, 2014
|------------------------ |  | ----------------- | ----- | ---------------
|                         |  |                   |       |                
|Computer                 |  | $                 | 3,853 |                
|Accumulated depreciation |  |                   | 1,927 |                
|                         |  | $                 | 1,926 |                



4. INTANGIBLE ASSET



On October 24, 2014, the Company entered into
a License Agreement with Life Medical Technologies, Inc. with respect to Life Medical’s “BreastCare DTSTM”
product and certain other technologies. The License Agreement grants the Company the exclusive right to distribute theBreastCare
DTSTMin the United States, Canada and certain countries in Asia, including China. The Agreement calls for royalties
of 5% on net sales, as defined in the License Agreement, and requires minimum annual royalties of $100,000 in 2015 and $200,000
each year thereafter.



The product is currently under development
and as such the costs associated with the license agreement are not yet being amortized.

Table of Contents8





EVENT CARDIO GROUP INC.

NOTES TO FINANCIAL STATEMENTS

February 28, 2015 and August 31, 2014



5. PAYABLES PURSUANT TO LICENSE AGREEMENT



As part of entering into the License Agreement
described in Note 4, the Company entered into release agreements with certain creditors of Life Medical Technologies, Inc. which
held judgments against Life Medical in the aggregate amount of approximately $501,000. Pursuant to the Release Agreements, the
Company agreed to pay those Creditors an aggregate of $501,064, satisfied through the issuance of common shares, as described
in Note 9, valued at $376,064 and payment of $125,000 cash ($12,500 which remains unpaid at February 28, 2015). The remaining
$12,500 was paid on March 10, 2015.



6. DUE TO RELATED PARTIES



The amounts due to related parties are non-interest
bearing, with no fixed terms of repayment, are payable on demand and are unsecured. As of February 28, 2015 and August 31, 2014,
the amounts of due to related parties are $82,047 and $74,423 respectively.



7. LONG-TERM DEBT - RELATED PARTIES



As at February 28, 2015, the Company has a promissory note outstanding
to 2399371 Ontario Inc., a company owned by an affiliate, for $583,000 Canadian ($466,109 US$) bearing interest at 12% per annum,
payable on December 1, 2015.



In connection with the entry into the License Agreement described in Note 4, the Company borrowed
CAD $79,106 ($63,245 US$) to be repaid on December 1, 2015, together with interest at the rate of 12% per annum from 9058583 Canada
Inc., a corporation owned by affiliates. In conjunction with this loan, the Company entered into a Sublicense agreement with 9508583
Canada Inc. whereby 9508583 Canada Inc. will be granted the exclusive rights to distribute the BreastCare DTSTMproduct
in Canada with royalties payable at the rate of 5.5% of net sales, as to be defined in the Sublicense Agreement, to the Company.



8. BUSINESS COMBINATION



On September 8, 2014, the Company entered into
a share exchange agreement with 2340960 Ontario Inc.'s shareholders whereby the Company acquired all of the issued and outstanding
common shares of 2340960 Ontario Inc. in exchange for 79,500,000 common shares of the Company. Upon completion of this transaction,
the shareholders of 2340960 Ontario Inc. held approximately 93.6% of voting control of the Company. This transaction, has been
accounted for as a reverse merger with 2340960 Ontario Inc. being the acquirer and the Company being the acquiree. As part of
this transaction, the Company has changed its fiscal year end from September 30th to August 31st.



9. STOCKHOLDERS' DEFICIT



Common Shares and Common Share Purchase
Warrant Issuance



On November 9, 2014, the Company issued 700,000
common shares for proceeds of $100,000.



On January 6, 2015, the Company issued 2,827,548
common shares valued at $376,064 in satisfaction of an obligation related to a license agreement as described in Note 5. The common
shares were valued using the volume weighted average price of the company's common stock as reported by Bloomberg for the five
consecutive trading days ending on the day before the 15th calendar day after consummation of this share exchange.

Table of Contents9





EVENT CARDIO GROUP INC.

NOTES TO FINANCIAL STATEMENTS

February 28, 2015 and August 31, 2014



9. STOCKHOLDERS’ DEFICIT (continued)



On January 30, 2015, the company issued 250,000
common shares and 250,000 common share purchase warrants for total proceeds of $25,000. The total proceeds of $25,000 have been
allocated to common shares and common share purchase warrants using the relative fair value method in the amounts of $13,945 and
$11,055 respectively. The common shares issued had a fair value of $25,000 based on the market price of $0.10 per common share
as of the close of trading on the date prior to this transaction. The common share purchase warrants had a fair value of $19,820
using the black-scholes pricing model, based on the terms of the common share purchase warrants noted below and the following
key assumptions used:



Risk-free interest rate	0.54%

Expected life	1 year

Price validity	288%

Dividend yield	Nil



On February 2, 2015, the Company issued 800,000
common shares for proceeds of $72,000.



On February 2, 2015, the Company issued 4,300,000
common shares in exchange for service agreements for a fair value of $387,000, based on the market price of $0.09 per common share
as of the measurement date.



Common Share Purchase Warrants



As of February 28, 2015 there are 250,000 common
share purchase warrants issued and outstanding. Each warrant allows the holder to purchase 1 common share of the company at an
exercise price of $0.20 per warrant up to the expiration date of January 31, 2016.



Equity Incentive Plan



The Company has created the Event Cardio Group
Inc. 2015 Equity Incentive Plan ("equity incentive plan") which allows for thegranting of incentive stock options
to employees of the company, a parent or a subsidiary and the granting of awards other than incentive stock options to employees,
directors and consultants. The maximum number of common shares which may be issued pursuant to the equity incentive plan at February
28, 2015 and February 28, 2014 is 10,000,000 and nil respectively. No incentive stock options or awards other than incentive stock
options have been granted as of February 28, 2015.



10. RELATED PARTY



The Company is related to Contex International
Technologies (Canada) Inc. ("Contex") through the fact that affiliates of the Company hold a 34% interest in 2419596
Ontario Inc, which owns Contex.



The Company has entered into a services
agreement with Contex, whereby Contex will provide services related to the design and development of a wireless and leadless ECG
cardiac monitor. The agreement runs for an initial term of one year to May 22, 2015 and will automatically renew for subsequent
terms of one year unless notice of termination is given by either party in writing.



As at February 28, 2015 and February
28, 2014, $178,994 and $nil respectively, have been incurred related to this agreement and have been expensed in research and
development expense.



See Note 7 regarding loans from related parties.

Table of Contents10





EVENT CARDIO GROUP INC.

NOTES TO FINANCIAL STATEMENTS

February 28, 2015 and August 31, 2014



11. SUBSCRIPTION AGREEMENT FOR CONVERTIBLE NOTES



The company is offering, pursuant to a Regulation
S Subscription Agreement and Investment Representation dated February 3, 2015, up to $2,000,000 of 8% convertible notes with interest
payable annually on January 31st. The holder upon written notice to the company may elect to have accrued but unpaid interest
added to the principal amount of the note in lieu of payment of interest. The principal amount of the note is payable on January
31, 2018. The note, or any part thereof and any unpaid interest is convertible into common shares of the company at any time at
the option of the holder at a conversion price of $0.15 per common share. The note may be prepaid at any time in full by the company
upon ten days notice to the holder.



As at February 28, 2015 no convertible notes have been issued
under this offering.



12. SUBSEQUENT EVENTS



Convertible Note Issuance and Distribution
Agreement



As of April 14, 2015, the company has received
$423,000 of the first tranche of $500,000 of the offering described in Note 11 from Medpac Asia Pacific PTY Ltd. of Australia
("Medpac"). Once the full $500,000 is received from Medpac the company will issue an 8% Convertible Note in the principal
amount of $500,000. In addition to the terms of the convertible note described in Note 11, for this tranche only, if the note
is prepaid by the company at any time prior to the maturity date, if the volume weighted average price of the common shares of
the company for the ten trading days preceding the early repayment date is less than $0.15 per common share, then Medpac shall
receive a number of common share purchase warrants sufficient to purchase up to 1% of the then outstanding number of common shares
of the Company. Such common share purchase warrants once issued would be exercisable for a period of three years at an exercise
price of $0.15 per common share, but may be exercised on a cashless basis.



A representative of Medpac will receive for its services
as part of this transaction a convertible note in the principal amount of $25,000 having the terms and conditions identical to
Medpac's note, except that the number of common share purchase warrants potentially issuable upon early payment of the note would
be sufficient to only purchase up to 0.0005% of the then outstanding common shares of the company.



The company plans to use the proceeds of the
first tranche of the offering as follows: Development of BreastCare product - $350,000; Development of Heart Monitor - $100,000;
legal fees - $25,000 and incidentals - $25,000.



In conjunction with Medpac's investment noted
above, the Company has agreed to enter into an exclusive Distribution Agreement with Medpac for the Company's BreastCare DTS TM
and Now Cardio devices in Australia, New Zealand, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Laos, Cambodia
Myanmar and Bangladesh. The Distribution Agreement will have an initial term of five years and can be renewed for an additional
five years provided that agreed upon sales targets are met. If the company does not establish a manufacturing facility for its
BreastCare DTSTM device in Southeast Asia within eighteen months of this agreement, Medpac and the company will form
a joint venture to establish such a facility in the Philippines.

Table of Contents11







EVENT CARDIO GROUP INC.

NOTES TO FINANCIAL STATEMENTS

February 28, 2015 and August 31, 2014



12. SUBSEQUENT EVENTS (continued)



Investment Agreement



On March 15, 2015, the Company entered
into an Investment Agreement with R.J. Capital Management, Ltd. a Hong Kong corporation ("RJ Capital"). The Agreement,
which is non-binding, provides for an investment by RJ Capital of $4 million for approximately 24,250,000 common shares to be
issued from treasury, with actual final number of common shares issued to represent 20% of the outstanding shares of the company
on a fully diluted basis on the date of issuance. The Agreement further provides for the formation of a Joint Venture which is
to be granted the exclusive right to manufacture and distribute the company's BreastCare DTSTM in China. RJ Capital
is to contribute $4 million to this Joint Venture and the company is to contribute $1 million, for which it will receive a 20%
interest in the Joint Venture. RJ Capital will have the right to invest an additional $5 million prior to dilution of the company's
20% interest in the joint venture. The company will use the proceeds to commercialize the BreastCare DTSTM device
in North America and China. As of April 14, 2015, the Company and RJ Capital were continuing to negotiate the specific terms under
which RJ Capital will make its invetstment in the Company. There is no assurance that the ongoing negotiations with RJ Capital
will result in an investment in the Company on the terms set forth in the Investment Agreement, if at all.

Table of Contents12





ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS



This Quarterly Report on Form 10-Q contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements
regarding our future results of operations and financial position, business strategy and plans and our objectives for future operations.
The words “may,” “will,” “should,” “could,” “expect,” “anticipate,”
“believe,” “estimate,” “intend,” “continue” and other similar expressions are
intended to identify forward-looking statements. We have based these forward looking statements largely on current expectations
and projections about future events and financial trends that we believe may affect our financial condition, results of operations,
business strategy, short term and long-term business operations and objectives, and financial needs. These forward-looking statements
involve risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in our
forward-looking statements. Such risks and uncertainties include, among others, those discussed in our consolidated financial
statements, related notes, and the other financial information appearing elsewhere in this report and our other filings with the
Securities and Exchange Commission, or the SEC, particularly those contained in the Section entitled “Risk Factors”
in our Form 10-K filed with the SEC on January 8, 2015. Moreover, we operate in a very competitive and rapidly changing environment.
New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of
all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially
from those contained in any forward-looking statements we may make. We do not intend, and undertake no obligation, to update any
of our forward-looking statements after the date of this report to reflect actual results or future events or circumstances. Given
these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements.



Our fiscal year ends on August 31 each year.



OVERVIEW



Event Cardio Group Inc. and its subsidiaries (collectively, “ECGI”, “we”,
“our” or the “Company”) were organized on October 26, 2005 and have had no operations since December,
2008, when we discontinued our previous business of mineral exploration. Most of our activities since January, 2009 have been
centered on the acquisition of a new business.



On June 9, 2014 we experienced a change of control as a result of a transaction (the
“Transaction”) in which 1,412,619 shares of our common stock, par value $0.001 and 10,000,000 shares of our preferred
stock, par value $0.001, constituting approximately 97% of the cumulative voting power of our capital stock on that date, was
acquired by Mr. John Bentivoglio, who is now our sole director and chief executive officer, as nominee for 2340960 Ontario Inc.,
a private company organized in Ontario, Canada, which is doing business as Event Cardio Group and which we hereinafter refer
to as “ECG”. The shares acquired of record by Mr. John Bentivoglio on June 9, 2014 are now owned beneficially and
of record by ECG. On September 8, 2014, we entered into a share exchange agreement (the “Exchange Agreement”), which
we consummated on November 14, 2014, pursuant to which we acquired all of the issued and outstanding capital stock of ECG from
ECG’s stockholders, The Nick Bozza Family Trust, The John Bentivoglio Family Trust and The Sgro (2010) Family Trust. In
exchange for all of the

outstanding capital stock of ECG, we issued to ECG’s stockholders an aggregate
of 79,500,000 shares of our Common Stock (the “Share Exchange”). As a result of the consummation of the Share Exchange,
(i) ECG became our wholly owned subsidiary and (ii) the ECG’s former stockholders own an aggregate of 79,500,000 shares
which constituted approximately 92.8% of the cumulative voting power of our common stock on the date the share exchange was consummated.



Mr. John Bentivoglio, our sole director and chief executive officer is one of three
trustees of The John Bentivoglio Family Trust, the beneficiaries of which are members of his family.



On October 24, 2014, through a wholly owned subsidiary, we entered into a license agreement
(the “License Agreement”) with Life Medical Technologies, Inc. (“Life Medical”) under which we were granted
the exclusive right to distribute Life Medical’s “BreastCare DTSTM” in the United States and certain other
territories. The BreastCare DTSTM product is a patented, non-invasive and FDA-cleared as an adjunct to mammography and other
established procedures for the detection of breast disease, including breast cancer.

Table of Contents13





GENERAL



The Exchange Agreement is accounted for a reverse merger, in which ECG is deemed to
be the acquiring entity for accounting purposes. The discussion and analysis of our financial condition and results of operations
is based upon the financial statements of ECG which have been prepared in accordance with accounting principles generally accepted
in the United States. The preparation of the Financial Statements requires the Company to make estimates and judgments that affect
the reported amounts of assets and liabilities. On an on-going basis, the Company estimates on historical experience and on various
other assumptions that, it believes to be reasonable under the circumstances, the results of which form the Company’s basis
for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual
results may differ from these estimates under different assumptions or conditions.



Reference is made to the Notes to the financial statements of 2340960 Ontario Inc. (which
we refer to in this Report as ECG) for the periods ended August 31, 2014 and August 31, 2013, which is filed as Exhibit 99.1 to
the Company’s Current Report on Form 8-K/A filed with the SEC on November 26, 2014 (the “Financial Statements”),
which should be read in conjunction with this Management Discussion below. The numbers and percentages contained in this Section
are approximate.



The Company cannot predict what future laws and regulations might be passed that could
have a material effect on its results of operations. The Company assesses the impact of significant changes in laws and regulations
on a regular basis and updates the assumptions and estimates used to prepare its financial statements when it deems necessary.



The Company’s primary sources of funding to date have been capital contributions
by its stockholders and cash provided by borrowings from affiliates. The Company’s primary uses of

funds have been for capital expenditures, general and administrative expenses and research
and development expenditures.



BASIS OF PRESENTATION



The unaudited consolidated financial statements have been prepared in accordance with
accounting principles generally accepted in the United States of America for interim financial statements and with the instructions
to Form 10-Q and Article 10 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly,
they do not contain all information and footnotes required by accounting principles generally accepted in the United States of
America for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited consolidated
financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial
position of the Company as of February 28, 2015 and the results of operations and cash flows for the periods presented. The results
of operations for the six months ended February 28, 2015 are not necessarily indicative of the operating results for the full
fiscal year or any future period. These consolidated financial statements should be read in conjunction with the consolidated
financial statements and related notes thereto included in the form 8-K/A filed with the SEC on November 26, 2014.



These financial statements contain the accounts of the Company and the accounts of the
Company’s subsidiaries 2340960 Ontario Inc. and EFIL Sub of ECG Inc. as at February 28, 2015 and August 31, 2014. Any inter-company
accounts and transactions are eliminated.



The financial statements have been prepared in conformity with accounting principles
generally accepted in the United States of America and are presented in United States Dollars.



RESULTS OF OPERATIONS



We have been in the developmental stage since inception. Since inception, our efforts
have been principally devoted to designing and developing a wireless cordless cardio monitor. From inception to February 28, 2015,
the Company has sustained losses and has an accumulated deficit of $1.053,360.

Table of Contents14





Our loss from operations for the six months ended February 28, 2015 was $535,985 compared
to a loss of $11,374 for the six months ended February 28, 2014. General and administrative expenses were $320,886 for the six
months ended February 28, 2015, compared to $11,374 for the six months ended February 28, 2014, an increase of $309,512. This
increase is predominately due to increased expenses related to the start-up of our business, the acquisition of the license from
Life Medical and expenses related operating as a public company.



Also, we incurred research and development expenses of $215,099 during the six months
ended February 28, 2015 as compared to $0 during the comparable period ended February 28, 2014, related to the development of
our cardiac monitoring device.



Total comprehensive loss for the six months ended February 28, 2015 was $499,533 as
compared to $11,374 for the period six months ended February 28, 2015. The increase in our loss resulted from the general and
administrative and research development expenses described above which began in earnest as a result of the reverse merger and
the efforts to develop our heart monitor.



LIQUIDITY AND CAPITAL RESOURCES



Period ended February 28, 2015 and August 31, 2014



As of February 28, 2015, our total assets were $931,008, total liabilities were $856,401
and stockholders’ equity was $74,607 compared to a deficit of $385,925 as of August 31, 2014. Current assets at February
28, 2015 were $407,134 consisting of cash of $52,384 and prepaid expenses of $354,750. In comparison, current assets at August
31, 2014 was $86,617, all of which was cash. The improvement in our stockholders equity reflects sales of 1,750,000 shares of
common stock and 250,000 warrants for total proceeds of $197,000, the issuance of shares valued at $387,000 for services rendered
or to be rendered by various consultants and the issuance of shares to satisfy various claims of Life Medical in connection with
obtaining the license agreement described below.



As of February 28, 2015, our total current liabilities of $327,047 consisted of stockholder
loans in the amount of $82,047, accounts payable of $232,500 and amounts due under the license agreement of $12,500.In comparison,
our current liabilities as of August 31, 2014 were $130,620, of which $74,423 was due to related parties. Our total liabilities
as of February 28, 2015, included long-term debts to related parties of $529,354 as compared to $384,978 due to related parties
as of August 31, 2014. The significant increase in our total liabilities as of February 28, 2015 compared to August 2014 resulted
from the increase in our accounts payable and the long-term borrowing from related parties to pay expenses related to our operational
activities which increased substantially in the current year.



The net cash used in our operating activities in the six months ended February 28, 2015
was $351,668, an increase of $351,133 from that used in the six-month period ended February 28, 2014. The substantial increase
in our use of cash reflects the increase in our development activities which commenced in earnest in the current fiscal year as
reflected in the increase in our operating loss which grew to $269,826 in the first six months of this year, copared to $11,374
in the first six months of the prior year.



Net cash used in investment activities in the six-months ended February 28, 2015 was
$112,500, as compared to $0 in the comparable period ended February 28, 2014, which increase was due to the acquisition of our
License Agreement with Life Medical. Net cash from financing activities in the six-months ended February 28, 2015 was $403,961,
, compared to $477 in the comparable period ended February 28, 2014, which increase reflects sales of our stock and warrants to
third parties as described above and an increase in our borrowings from related parties.



ECG has been in the developmental stage since inception. Since inception,
ECG’s efforts have been principally devoted to designing and developing a wireless cordless cardio monitor. From
inception to February 28, 2015, the Company has sustained losses and has an accumulated deficit of $1,053,360. The Company
has funded its activities to date primarily through contributions from its stockholders and loans from affiliates.

Table of Contents15





In May 2014, ECG entered into a loan agreement (the “May Loan Agreement”)
with an affiliated company, pursuant to which the lender agreed to lend the Company up to CAD $583,000. This loan bears interest
at the rate of 12% per annum, compounded monthly, and matures on December 1, 2015. ECG’s shareholders guaranteed ECG’s
obligations under the May Loan Agreement with recourse exclusively to the shares they owned of ECG. As a result of the Share Exchange,
we have agreed to guaranty ECG’s obligations under the May Loan Agreement and pledge the shares of ECG that we acquired
in the Shares Exchange to the lender as security for our guaranty. Our guaranty is secured by a lien on all of our assets. In
addition, our Controlling Stockholders guaranteed ECG’s obligations under the May Loan Agreement with recourse exclusively
to the shares of our common stock that they acquired in the Share Exchange. Under the terms of the May Loan Agreement, 50% of
the net proceeds we realize from the sale of our capital stock or from borrowings must be used to repay the amounts owned under
this Loan. As of February 28, 2015, $529,354) is outstanding under the May Loan Agreement.



We are required to pay Life Medical royalties of 5% on net sales, as defined in the
License Agreement, and minimum annual royalties of $100,000 in 2015 and $200,000 each year thereafter. In addition, we entered
into release agreements (the “Releases”) with certain creditors (the “Life Medical Creditors”) of Life
Medical which held judgments against Life Medical in the aggregate amount of approximately $501,000. Pursuant to the Release Agreements,
we agreed to pay the Life Medical Creditors an aggregate of $501,000, of which $125,000 was to be paid in cash and the balance
was to be satisfied by the issuance of shares of our common stock valued at $376,064.05, with the number of shares of common stock
to be determined by dividing 376,064.05 by the volume weighted average price (“VWAP”) of our common stock as reported
by Bloomberg for the five (5) consecutive trading days ending on the day before the 15th calendar day after consummation of the
Share Exchange. On January 6, 2015, we issued 2,827,548 shares of our common stock in satisfaction of this obligation. The recipients
of shares valued at $70,000 are also to be paid in cash or shares of common stock, at our option, an amount equal to the excess,
if any, of $70,000 over the value of such shares as of December 12, 2015. The License Agreement recognizes that in order to protect
our interests, we may have to spend monies dealing with creditors of and other claimants against Life Medical. Although we have
no obligation to consummate arrangements with such creditors, we may reduce any amounts we pay to Life Medical’s creditors
from future amounts payable to Life Medical. We are currently conducting due diligence for the product, the strength of underlying
patents, the status of required regulatory approvals and how this product can most efficiently be manufactured.



In connection with the License Agreement with Life Medical, in October 2014 we borrowed
CAD $79,106 (the “October Loan”) from an Ontario corporation owned in equal thirds by John Bentivoglio, Nicholas Bozza
and Frank Sgro (the “Lender”), all of whom are affiliates of the Company. This loan bears interest at the rate of
12% per annum, compounded monthly and matures on December 1, 2015. Our obligations under this Loan are secured by a lien on all
of our

assets as well as pledge of the stock we own in our wholly owned subsidiary which entered
into the License Agreement.



As of February 28, 2015, we owed affiliates approximately $ 548,156.



We do not have substantial commitments for capital expenditures. However, we will require
financing to complete the development of our cardiac monitor, to arrange for the development of manufacturing facilities or arrangements
for both of our products and the working capital to support distribution efforts when our products are ready for sale. If we fail
to arrange for such financing in the future, we will not be able to complete the development of our cardiac monitor or execute
our business plan until we can obtain adequate financing, which we may not be successful in accomplishing. We may not be able
to obtain financing in sufficient amounts or on acceptable terms when needed, which will adversely affect our prospects. We will
need to raise the financing necessary to meet our anticipated cash requirements for the foreseeable future.



OFF BALANCE SHEET ARRANGEMENTS



We do not have any off-balance sheet arrangements, financings, or other relationships
with consolidated entities or other persons, also known as “special purpose entities”.

Table of Contents16





CRITICAL ACCOUNTING POLICIES



Our significant accounting policies are more fully described in Note 2 to the Financial
Statements provided in Part I, Item 1 of this report. The preparation of financial statements in conformity with accounting principles
generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported
amounts of assets, liabilities, revenues and expenses, and the related disclosures of contingent assets and liabilities. Actual
results could differ from those estimates under different assumptions or conditions.



ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.



As a smaller reporting company, this item is not applicable to us.



ITEM 4. CONTROLS AND PROCEDURES



a) Disclosure Controls and Procedures



We maintain "disclosure controls and procedures," as such term is defined
in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act"), that are designed to
ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed,
summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such
information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer,
as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and
procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide
only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally,
in designing disclosure controls and procedures, our management was required to apply its judgment in evaluating the cost-benefit
relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based
in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed
in achieving its stated goals under all potential future conditions.



At the end of the period covered by this report we carried out an evaluation, under
the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, John Bentivoglio, of the
effectiveness of the design and operation of our disclosure controls and procedures. This evaluation included an evaluation of
our financial controls. Since our Chief Executive Officer also serves as our Chief Financial Officer and we do not have financial
and accounting personnel thoroughly familiar with U.S. GAAP and U.S. securities laws and regulations, we have a deficiency in
our financial controls. This deficiency in our financial controls and procedures constitutes a deficiency in our disclosure controls
and procedures in that our disclosure controls and procedures were not effective to ensure that information required to be disclosed
by us in our periodic reports is recorded, processed, summarized and reported, within the time periods specified for each report
and that such information is accumulated and communicated to our management, including our principal executive and principal financial
officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. This
deficiency will not be considered remediated until we hire accounting personnel with the requisite knowledge and experience concerning
U.S. GAAP and the U.S. securities laws.



b) Changes in Internal Control over Financial Reporting



There were no changes in the Company's internal control over financial reporting that
occurred during the last fiscal quarter ended February 28, 2015, that materially affected, or are reasonably likely to materially
affect, the Company's internal control over financial reporting.

Table of Contents17





PART II. OTHER INFORMATION



ITEM 1. LEGAL PROCEEDINGS



From time to time, we may be involved in various legal proceedings in the ordinary course
of business. We do not believe that any settlement or judgment regarding current or potential future legal proceedings will have
a material effect on our financial position.



ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS FROM SALES OF
REGISTERED SECURITIES



None.



ITEM 3. DEFAULTS UPON SENIOR SECURITIES



None.



ITEM 4. MINE SAFETY DISCLOSURES



None.



ITEM 5. OTHER INFORMATION



None.



ITEM 6. EXHIBITS



Exhibits



|21 |  | List of subsidiaries
|-- |  | --------------------



|31 |  | Sec. 302 Certification of CEO/CFO
|-- |  | ---------------------------------



|32 |  | Sec. 906 Certification of CEO/CFO
|-- |  | ---------------------------------







Table of Contents18





SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



|                      | Event Cardio Group Inc.
|--------------------- | -----------------------
|                      |                        
|Dated: April 15, 2015 | By:                    
|                      | Name:
        Title:   



Table of Contents19